Does teneligliptin reverse the metabolic syndrome components among non-diabetic obesity subjects? – A hypothesis

Keywords: teneligliptin, obesity, non-diabetics, metabolic syndrome, GLP-1


Obesity and its related metabolic syndrome complications are highly remarkable and need to be addressed. There are a limited number of anti-obesity drugs available, and there is a need for more safe and effective therapeutic options for treating obesity. Currently, drug repurposing is an alternative to novel drug development for the treatment of obesity patients. Teneligliptin is an oral anti-diabetic agent, and it was well tolerated. In addition to anti-diabetic activity, teneligliptin conserves endogenous incretins by inhibiting the dipeptidyl peptidase -4 enzyme. Incretins play a vital role in obesity and its related complications. Several pre-clinical studies with teneligliptin support ameliorated the metabolic syndrome in obesity without diabetes in Zucker fatty rats. Till now, there have been no studies on the obese population without diabetes. Hence, we hypothesize that teneligliptin 20 mg twice daily with a low carbohydrate diet and adequate physical activity may be more effective in reversing metabolic syndrome and obesity.